A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma." ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results